Latest & greatest articles for type 2 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 2 diabetes

121. Free and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials

Free and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials 29732679 2018 05 25 1463-1326 2018 May 07 Diabetes, obesity & metabolism Diabetes Obes Metab Free and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in type 2 diabetes: A systematic review and meta-analysis of randomized controlled (...) trials. 10.1111/dom.13343 A meta-analysis is presented of randomized controlled trials (RCTs) comparing free or fixed combinations of a glucagon-like peptide-1 receptor agonist plus basal insulin versus insulin intensification on metabolic control in patients with type 2 diabetes. Electronic databases were searched for RCTs assessing changes in HbA1c, proportion of patients at HbA1c target of <7% (53 mmol/mol), hypoglycaemia and body weight. A random-effect model was used to calculate the weighted

EvidenceUpdates2018

122. Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial

Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial 29766636 2018 06 01 1463-1326 2018 May 15 Diabetes, obesity & metabolism Diabetes Obes Metab Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial. 10.1111 (...) /dom.13352 This double-blind, randomized, placebo-controlled trial (ClinicalTrials.gov NCT02453555) evaluated the efficacy and safety of empagliflozin (Empa) 10 or 25 mg as add-on to linagliptin (Lina) 5 mg (fixed-dose combination, Empa/Lina 10/5 or 25/5) in insufficiently controlled Japanese type 2 diabetes patients. The trial (40 sites; May 2015-March 2017) involved screening 433 adults (≥20 years) who were treatment-naive or were using one oral antidiabetic drug for ≥12 weeks, which

EvidenceUpdates2018

123. Mini-Dose Glucagon as a Novel Approach to Prevent Exercise-Induced Hypoglycemia in Type 1 Diabetes

Mini-Dose Glucagon as a Novel Approach to Prevent Exercise-Induced Hypoglycemia in Type 1 Diabetes 29776987 2018 05 19 1935-5548 2018 May 18 Diabetes care Diabetes Care Mini-Dose Glucagon as a Novel Approach to Prevent Exercise-Induced Hypoglycemia in Type 1 Diabetes. dc180051 10.2337/dc18-0051 Patients with type 1 diabetes who do aerobic exercise often experience a drop in blood glucose concentration that can result in hypoglycemia. Current approaches to prevent exercise-induced hypoglycemia (...) include reduction in insulin dose or ingestion of carbohydrates, but these strategies may still result in hypoglycemia or hyperglycemia. We sought to determine whether mini-dose glucagon (MDG) given subcutaneously before exercise could prevent subsequent glucose lowering, and to compare the glycemic response to current approaches for mitigating exercise-associated hypoglycemia. We conducted a four-session, randomized crossover trial involving 15 adults with type 1 diabetes treated with continuous

EvidenceUpdates2018

124. Alogliptin (Nesina) - type 2 diabetes mellitus

Alogliptin (Nesina) - type 2 diabetes mellitus Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Summary Basis of Decision (SBD) for Contact: Summary basis of decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent activity SBDs written for approved after September 1, 2012 will be updated (...) /submission type, control number Date submitted Decision and date Summary of activities Summary basis of decision for Date SBD issued: The following information relates to the original authorization of the new drug submission for . Drug identification number (DIN): 1 What was approved? 2 Why was approved? 3 What steps led to the approval of ? Submission Milestones: Submission milestone Date 4 What follow-up measures will the company take? 5 What post-authorization activity has taken place for ? 6 What

Health Canada - Drug and Health Product Register2018

125. Albiglutide (Eperzan) - type 2 diabetes mellitus

Albiglutide (Eperzan) - type 2 diabetes mellitus Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Summary Basis of Decision (SBD) for Contact: Summary basis of decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent activity SBDs written for approved after September 1, 2012 will be updated (...) /submission type, control number Date submitted Decision and date Summary of activities Summary basis of decision for Date SBD issued: The following information relates to the original authorization of the new drug submission for . Drug identification number (DIN): 1 What was approved? 2 Why was approved? 3 What steps led to the approval of ? Submission Milestones: Submission milestone Date 4 What follow-up measures will the company take? 5 What post-authorization activity has taken place for ? 6 What

Health Canada - Drug and Health Product Register2018

126. Lower Renal Function Is Associated With Derangement of 11-β Hydroxysteroid Dehydrogenase in Type 2 Diabetes

Lower Renal Function Is Associated With Derangement of 11-β Hydroxysteroid Dehydrogenase in Type 2 Diabetes 29942925 2018 11 14 2472-1972 2 7 2018 Jul 01 Journal of the Endocrine Society J Endocr Soc Lower Renal Function Is Associated With Derangement of 11- β Hydroxysteroid Dehydrogenase in Type 2 Diabetes. 609-620 10.1210/js.2018-00088 Derangement of 11- β hydroxysteroid dehydrogenase type 1 and type 2 (11 β -HSD1 and 11 β -HSD2), which regulate intracellular cortisol production, has been (...) suggested in both type 2 diabetes (T2D) and chronic kidney disease (CKD). However, activity of 11 β -HSD enzymes in patients with T2D and CKD has never been assessed. To compare 11 β -HSD activities between patients with T2D and healthy controls, and assess whether in T2D, renal function is associated with 11 β -HSD activities. Cross-sectional analysis in the Diabetes and Lifestyle Cohort Twente (DIALECT-1). Referral center for T2D. Patient with T2D [n = 373, age 64 ± 9 years, 58% men, 26% of patients

Journal of the Endocrine Society2018 Full Text: Link to full Text with Trip Pro

127. Factors associated with self‐management among Vietnamese adults with type 2 diabetes

Factors associated with self‐management among Vietnamese adults with type 2 diabetes 30338096 2018 11 14 2054-1058 5 4 2018 Oct Nursing open Nurs Open Factors associated with self-management among Vietnamese adults with type 2 diabetes. 507-516 10.1002/nop2.158 The study described diabetes self-management (DSM), diabetes knowledge, family and friends' support, healthcare providers' support, belief in treatment effectiveness and diabetes management self-efficacy, and explored DSM's (...) associations among Vietnamese adults with type 2 diabetes mellitus (T2DM). A cross-sectional design was applied. The study used self-report questionnaires to collect data from 198 participants. Descriptive statistics and structural equation modelling (SEM) was used for data analysis. Vietnamese adults with T2DM performed DSM limitedly in certain aspects. They had strong belief in treatment effectiveness, good family and friends support, limited diabetes knowledge, healthcare professional support and self

Nursing open2018 Full Text: Link to full Text with Trip Pro

128. Hesperidin, a plant flavonoid accelerated the cutaneous wound healing in streptozotocin-induced diabetic rats: Role of TGF-ß/Smads and Ang-1/Tie-2 signaling pathways

Hesperidin, a plant flavonoid accelerated the cutaneous wound healing in streptozotocin-induced diabetic rats: Role of TGF-ß/Smads and Ang-1/Tie-2 signaling pathways 29805347 2018 11 14 1611-2156 17 2018 EXCLI journal EXCLI J Hesperidin, a plant flavonoid accelerated the cutaneous wound healing in streptozotocin-induced diabetic rats: Role of TGF-ß/Smads and Ang-1/Tie-2 signaling pathways. 399-419 10.17179/excli2018-1036 Background: Delayed wound healing is a diverse, multifactorial, complex (...) angiogenesis and vasculogenesis via up-regulation of VEGF-c, Ang-1/Tie-2, TGF-β and Smad-2/3 mRNA expression to enhance wound healing in chronic diabetic foot ulcers. Li Wenbin W Department of Dermatology, Shaanxi Traditional Chinese Medicine Hospital, Xi'an, Shaanxi, 710003, China. Kandhare Amit D AD Department of Pharmacology, Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Erandwane, Paud Road, Pune-411 038, India. Jalan Universiti Bandar Barat, 31900, Kampar, Perak, Malaysia. Mukherjee

EXCLI journal2018 Full Text: Link to full Text with Trip Pro

129. Continuous monitoring of glucose for Type 1 diabetes: OHTAC recommendation

Continuous monitoring of glucose for Type 1 diabetes: OHTAC recommendation Continuous monitoring of glucose for Type 1 diabetes: OHTAC recommendation Continuous monitoring of glucose for Type 1 diabetes: OHTAC recommendation Health Quality Ontario Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Health Quality Ontario. Continuous (...) monitoring of glucose for Type 1 diabetes: OHTAC recommendation. Toronto: Health Quality Ontario (HQO). 2018 Authors' conclusions Health Quality Ontario, under the guidance of the Ontario Health Technology Advisory Committee, recommends publicly funding continuous glucose monitoring in patients with type 1 diabetes who are willing to use continuous glucose monitoring for the vast majority of the time and who meet one or more of the following criteria: • Severe hypoglycemia without an obvious precipitant

Health Technology Assessment (HTA) Database.2018

130. Continuous monitoring of glucose for Type 1 Diabetes: a health technology assessment

Ontario. Continuous monitoring of glucose for Type 1 Diabetes: a health technology assessment. Toronto: Health Quality Ontario (HQO). Ontario Health Technology Assessment Series; 18(2). 2018 Authors' conclusions Continuous glucose monitoring was more effective than self-monitoring of blood glucose in managing type 1 diabetes for some outcomes, such as time spent in the target glucose range and time spent outside the target glucose range (moderate certainty in this evidence). We were less certain (...) Continuous monitoring of glucose for Type 1 Diabetes: a health technology assessment Continuous monitoring of glucose for Type 1 Diabetes: a health technology assessment Continuous monitoring of glucose for Type 1 Diabetes: a health technology assessment Health Quality Ontario Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Health Quality

Health Technology Assessment (HTA) Database.2018

131. Lixisenatide (Adlyxine) - type 2 diabetes mellitus

Lixisenatide (Adlyxine) - type 2 diabetes mellitus Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Summary Basis of Decision (SBD) for Contact: Summary basis of decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent activity SBDs written for approved after September 1, 2012 will be updated (...) /submission type, control number Date submitted Decision and date Summary of activities Summary basis of decision for Date SBD issued: The following information relates to the original authorization of the new drug submission for . Drug identification number (DIN): 1 What was approved? 2 Why was approved? 3 What steps led to the approval of ? Submission Milestones: Submission milestone Date 4 What follow-up measures will the company take? 5 What post-authorization activity has taken place for ? 6 What

Health Canada - Drug and Health Product Register2018

132. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis

Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis 29652101 2018 05 03 1463-1326 2018 Apr 13 Diabetes, obesity & metabolism Diabetes Obes Metab Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis. 10.1111/dom.13318 The recent LIRA-SWITCH trial showed that switching from sitagliptin 100 mg to liraglutide 1.8 mg led to statistically (...) significant and clinically relevant improvements in glycated haemoglobin (HbA1C) and body mass index (BMI). Based on these findings, the aim of the present study was to assess the long-term cost-effectiveness of switching from sitagliptin to liraglutide in patients with type 2 diabetes in the UK. The IQVIA CORE Diabetes Model Version 8.5+ was used to project costs and clinical outcomes over patients' lifetimes. Baseline cohort characteristics and treatment effects were derived from the LIRA-SWITCH trial

EvidenceUpdates2018

133. Cost-effectiveness of Continuous Glucose Monitoring for Adults With Type 1 Diabetes Compared With Self-Monitoring of Blood Glucose: the DIAMOND Randomized Trial

monitoring (CGM) in patients with type 1 diabetes (T1D) using multiple insulin injections. In the Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes (DIAMOND) trial, 158 patients with T1D and HbA 1c ≥7.5% were randomized in a 2:1 ratio to CGM or control. Participants were surveyed at baseline and 6 months. Within-trial and lifetime cost-effectiveness analyses were conducted. A modified Sheffield T1D policy model was used to simulate T1D complications. The main outcome was cost per (...) Cost-effectiveness of Continuous Glucose Monitoring for Adults With Type 1 Diabetes Compared With Self-Monitoring of Blood Glucose: the DIAMOND Randomized Trial 29650803 2018 04 13 1935-5548 2018 Apr 12 Diabetes care Diabetes Care Cost-effectiveness of Continuous Glucose Monitoring for Adults With Type 1 Diabetes Compared With Self-Monitoring of Blood Glucose: the DIAMOND Randomized Trial. dc171821 10.2337/dc17-1821 This study evaluated the societal cost-effectiveness of continuous glucose

EvidenceUpdates2018

134. Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial)

Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial) 29627109 2018 04 08 1879-1913 2018 Mar 15 The American journal of cardiology Am. J. Cardiol. Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial). S0002-9149(18)30266-2 10.1016/j.amjcard.2018.02.030 Diabetes mellitus (DM) is a known risk factor for myocardial infarction (MI (...) ); however, data regarding MI subtypes in people with diabetes are limited. In the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial (n = 9,340), liraglutide significantly reduced the risk of major adverse cardiovascular (CV) events (composite of CV death, nonfatal MI, or nonfatal stroke) versus placebo in patients with type 2 DM and high CV risk. Liraglutide also reduced risk of first MI (292 events with liraglutide vs 339 with placebo). This post hoc

EvidenceUpdates2018 Full Text: Link to full Text with Trip Pro

135. Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials

Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials 29451721 2018 03 25 1463-1326 2018 Feb 16 Diabetes, obesity & metabolism Diabetes Obes Metab Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials. 10.1111/dom.13260 New treatments for type 1 diabetes are an unmet (...) need. We investigated the efficacy and safety of adding sodium-glucose co-transporter-2 (SGLT2) inhibitors to insulin for type 1 diabetes by conducting a meta-analysis of prospective randomized, placebo-controlled trials. A search of electronic databases up to October 2017 identified 1361 studies, of which 14 were investigated (N = 4591). Meta-analysis showed that SGLT2 inhibitor therapy significantly reduced glycated haemoglobin (HbA1c) concentration by 0.4% (95% confidence interval [CI] 0.35

EvidenceUpdates2018

136. Hypoglycaemia incidence and recovery during home use of hybrid closed-loop insulin delivery in adults with type 1 diabetes

Hypoglycaemia incidence and recovery during home use of hybrid closed-loop insulin delivery in adults with type 1 diabetes 29577536 2018 04 16 1463-1326 2018 Mar 25 Diabetes, obesity & metabolism Diabetes Obes Metab Hypoglycaemia incidence and recovery during home use of hybrid closed-loop insulin delivery in adults with type 1 diabetes. 10.1111/dom.13304 Glucose excursion was assessed prior to and post hypoglycaemia to increase understanding of hypoglycaemia incidence and recovery during (...) hybrid closed-loop insulin delivery. We retrospectively analysed data from 60 adults with type 1 diabetes who received, in a crossover randomized design, day-and-night hybrid closed-loop insulin delivery and insulin pump therapy, the latter with or without real-time continuous glucose monitoring. Over 4-week study periods, we identified hypoglycaemic episodes, defined as sensor glucose <3.0 mmol/L, and analysed sensor glucose relative to the onset of hypoglycaemia. We identified 377 hypoglycaemic

EvidenceUpdates2018

137. SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta-analysis

SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta-analysis 29573118 2018 04 17 1463-1326 2018 Mar 23 Diabetes, obesity & metabolism Diabetes Obes Metab SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta-analysis. 10.1111/dom.13295 The effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on risk of stroke have not been conclusively established. Therefore, we conducted a meta-analysis (...) to evaluate the effects of SGLT2 inhibitors on stroke risk in patients with type 2 diabetes mellitus (T2DM) by searching available randomized trials in PubMed, Embase, CENTRAL, Web of Science, Scopus and ClinicalTrials.gov databases. We identified 32 eligible trials involving 75 540 participants. The incidence of stroke in groups receiving SGLT2 inhibitor monotherapy or combination therapy did not differ significantly from that in control groups, with a relative risk (RR) of 1.01 and 1.0, respectively

EvidenceUpdates2018

138. SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis

SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis 29573110 2018 04 14 1463-1326 2018 Mar 23 Diabetes, obesity & metabolism Diabetes Obes Metab SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis. 10.1111/dom.13294 To assess the efficacy and safety of sodium-glucose co-transporter 2 (SGLT2) inhibitors plus a dipeptidyl peptidase-4 (DPP-4) inhibitor in patients (...) with type 2 diabetes mellitus (T2DM), we performed a systematic review and meta-analysis of 14 randomized controlled trials (RCTs) involving 4828 patients. Compared with a DPP-4 inhibitor, SGLT2 inhibitor/DPP-4 inhibitor combination therapy was significantly associated with a decrease in glycaemic control (HbA1c, -0.71%; fasting plasma glucose [FPG], -25.62 mg/dL; postprandial plasma glucose, -44.00 mg/dL), body weight (-2.05 kg) and systolic blood pressure (-5.90 mm Hg), but an increase in total cholesterol (TC

EvidenceUpdates2018

139. Use of a metabolomic approach to non-invasively diagnose non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus

Use of a metabolomic approach to non-invasively diagnose non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus 29527789 2018 04 14 1463-1326 2018 Mar 12 Diabetes, obesity & metabolism Diabetes Obes Metab Use of a metabolomic approach to non-invasively diagnose non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. 10.1111/dom.13285 To assess the utility of existing metabolomics scores to classify liver disease in patients with type 2 diabetes mellitus (...) (areas under the receiver-operating characteristic [AUROC] curve both <0.70). Given the discordance of these results in this heterogeneous, multiethnic cohort compared with those of a previous report in predominantly white patients without diabetes, we examined the influence of age, ethnicity and other variables on test performance. A specific subset of patients was selected to mirror the characteristics of the population used for the development of this model (ie, white patients without T2DM). Among

EvidenceUpdates2018

140. Intermittent fasting in Type 2 diabetes mellitus and the risk of hypoglycaemia: a randomized controlled trial

Intermittent fasting in Type 2 diabetes mellitus and the risk of hypoglycaemia: a randomized controlled trial 29405359 2018 04 16 1464-5491 35 5 2018 May Diabetic medicine : a journal of the British Diabetic Association Diabet. Med. Intermittent fasting in Type 2 diabetes mellitus and the risk of hypoglycaemia: a randomized controlled trial. 588-594 10.1111/dme.13595 To establish whether the risk of hypoglycaemia is greater with 2 consecutive days of very-low-calorie diet compared with 2 non (...) -consecutive days of very-low-calorie diet in people with Type 2 diabetes. This was a non-blinded randomized parallel group interventional trial of intermittent fasting in adults. The participants had a BMI of 30-45 kg/m 2 , Type 2 diabetes treated with metformin and/or hypoglycaemic medications and an HbA 1c concentration of 50-86 mmol/mol (6.7-10%). The participants followed a 2092-2510-kJ diet on 2 days per week for 12 weeks. A total of 41 participants were randomized 1:1 to consecutive (n=19) or non

EvidenceUpdates2018